COMMUNIQUÉS West-GlobeNewswire

Considering MEDVi QUAD in 2026? Read This Before Enrolling in Any Compounded ED Telehealth Program
26/02/2026
An informational overview of publicly available disclosures, regulatory context, and verification steps consumers commonly review before starting compounded erectile dysfunction treatment through telehealth. NEWARK, DE [...]
MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001
26/02/2026
SHANGHAI, China, Feb. 25, 2026 (GLOBE NEWSWIRE) -- MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first patient has been dosed in the Phase III [...]
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
25/02/2026
GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
25/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
25/02/2026
LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46 th Annual Health Care Conference [...]
OraSure Announces Fourth Quarter 2025 Financial Results
25/02/2026
BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
25/02/2026
On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026 Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three [...]
Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results
25/02/2026
Fourth quarter revenue of $15.2 million; 61% growth YoY Full year revenue of $50.5 million; 86% growth YoY CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company [...]
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
25/02/2026
FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income ( 1) of $161 Million, [...]
Park Dental Partners Announces Fourth Quarter and Full-Year Results
25/02/2026
MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK) and affiliated dental practices (“Park Dental Partners,” “we,” “our,” “us,” or the “Company”) today reported its fourth-quarter [...]
PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
25/02/2026
SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions [...]
Chemed Reports Fourth-Quarter 2025 Results
25/02/2026
CINCINNATI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation [...]
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
25/02/2026
Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027 Phase 3 [...]
Teladoc Health Reports Fourth Quarter and Full Year 2025 Results
25/02/2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 (“Fourth Quarter 2025”) and [...]
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
25/02/2026
Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10 , Respectively Fourth Quarter Adjusted EBITDA 1 was $29 [...]
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
25/02/2026
FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be [...]
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
25/02/2026
Q4 2025 net product revenue for ZORYVE ® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025 Full year 2025 net product revenue for ZORYVE was $372.1 million, an [...]
Celcuity To Participate in Upcoming Investor Conferences
25/02/2026
MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief [...]
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
25/02/2026
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]

Pages